EGFR and neoplasm: The TAT from tumor sampling to initiation of EGFR-TKI was 7.7 ± 1.2 wd (11.4 ± 3.1 cd) when the decision was based on the IdyllaTM method, while it was 20.3 ± 6.7 wd (27.2 ± 8.3 cd) when the decision was based on the NGS method, i.e., reduced by more than two-fold with the IdyllaTM system (p < 0.001).